{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:17:29Z","timestamp":1788355049192,"version":"build-2803163510"},"reference-count":15,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"DOI":"10.1111\/bjh.70794","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:31:24Z","timestamp":1788352284000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment\u2010free remission in\n                    <scp>CML<\/scp>\n                    patients with prior\n                    <scp>TKI<\/scp>\n                    failure is not influenced by previous\n                    <i>BCR::ABL1<\/i>\n                    kinase domain mutations"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-7610","authenticated-orcid":false,"given":"Simone","family":"Claudiani","sequence":"first","affiliation":[{"name":"Centre for Haematology, Department of Immunology and Inflammation Faculty of Medicine, Imperial College London  London UK"},{"name":"Department of Haematology Hammersmith Hospital, Imperial College Healthcare NHS Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Metelli","sequence":"additional","affiliation":[{"name":"Centre of Research in Epidemiology and Statistics (CRESS) University of Paris, INSERM, INRA  Paris France"},{"name":"Assistance Publique \u2010 H\u00f4pitaux de Paris (APHP)  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6028-5676","authenticated-orcid":false,"given":"Myrto","family":"Katraki","sequence":"additional","affiliation":[{"name":"North West London Pathology, Hammersmith Hospital Imperial College Healthcare NHS Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7031-5054","authenticated-orcid":false,"given":"Fiona","family":"Fernando","sequence":"additional","affiliation":[{"name":"Centre for Haematology, Department of Immunology and Inflammation Faculty of Medicine, Imperial College London  London UK"},{"name":"Department of Haematology Hammersmith Hospital, Imperial College Healthcare NHS Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0918-8882","authenticated-orcid":false,"given":"Andrew J.","family":"Innes","sequence":"additional","affiliation":[{"name":"Centre for Haematology, Department of Immunology and Inflammation Faculty of Medicine, Imperial College London  London UK"},{"name":"Department of Haematology Hammersmith Hospital, Imperial College Healthcare NHS Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Hayden","sequence":"additional","affiliation":[{"name":"North West London Pathology, Hammersmith Hospital Imperial College Healthcare NHS Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana","family":"Milojkovic","sequence":"additional","affiliation":[{"name":"Centre for Haematology, Department of Immunology and Inflammation Faculty of Medicine, Imperial College London  London UK"},{"name":"Department of Haematology Hammersmith Hospital, Imperial College Healthcare NHS Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"issue":"1","key":"e_1_2_2_2_1","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s12672-024-01444-9","article-title":"Treatment\u2010free remission after discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a systematic review and meta\u2010analysis","volume":"15","author":"Zheng Z","year":"2024","journal-title":"Discov Oncol"},{"issue":"7","key":"e_1_2_2_3_1","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G\u2010TKI study","volume":"129","author":"Rea D","year":"2017","journal-title":"Blood"},{"issue":"5","key":"e_1_2_2_4_1","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.3324\/haematol.2019.234179","article-title":"Prolonged treatment\u2010free remission in chronic myeloid leukemia patients with previous BCR\u2010ABL1 kinase domain mutations","volume":"105","author":"Claudiani S","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"e_1_2_2_5_1","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/bjh.18883","article-title":"Treatment\u2010free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: final 5\u2010year analysis of DASFREE","volume":"202","author":"Shah NP","year":"2023","journal-title":"Br J Haematol"},{"issue":"5","key":"e_1_2_2_6_1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clml.2018.03.004","article-title":"Final 3\u2010year results of the Dasatinib discontinuation trial in patients with chronic myeloid leukemia who received Dasatinib as a second\u2010line treatment","volume":"18","author":"Okada M","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"e_1_2_2_7_1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-024-01025-7","article-title":"A successful treatment\u2010free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements","volume":"14","author":"Bonifacio M","year":"2024","journal-title":"Blood Cancer J"},{"key":"e_1_2_2_8_1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1154377","article-title":"Treatment discontinuation following low\u2010dose TKIs in 248 chronic myeloid leukemia patients: updated results from a campus CML real\u2010life study","volume":"14","author":"Iurlo A","year":"2023","journal-title":"Front Pharmacol"},{"key":"e_1_2_2_9_1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1101743","article-title":"Successful treatment discontinuation in CML patients with full\u2010dose and low\u2010dose TKI: results from real\u2010world practice","volume":"14","author":"Chen Y","year":"2023","journal-title":"Front Pharmacol"},{"issue":"8","key":"e_1_2_2_10_1","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley JF","year":"2025","journal-title":"Leukemia"},{"issue":"9","key":"e_1_2_2_11_1","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/cncr.20975","article-title":"Phase I\/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib","volume":"103","author":"Marin D","year":"2005","journal-title":"Cancer"},{"issue":"7","key":"e_1_2_2_12_1","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/s41375-019-0700-9","article-title":"A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease","volume":"34","author":"Horne GA","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"e_1_2_2_13_1","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1002\/ajh.27073","article-title":"Risk of progression in chronic phase\u2010chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: final analysis of the TFR\u2010PRO study","volume":"98","author":"Zambrotta GPM","year":"2023","journal-title":"Am J Hematol"},{"issue":"4","key":"e_1_2_2_14_1","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/bjh.70080","article-title":"Treatment\u2010free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure","volume":"207","author":"Yuan M","year":"2025","journal-title":"Br J Haematol"},{"issue":"5","key":"e_1_2_2_15_1","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander M","year":"2017","journal-title":"Leukemia"},{"key":"e_1_2_2_16_1","article-title":"Rapid development of Philadelphia chromosome\u2010negative AML in a CML patient with sustained major molecular response to tyrosine kinase inhibitor therapy","volume":"24","author":"Liu H","year":"2025","journal-title":"Leuk Res Rep"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70794","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.70794","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70794","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:31:26Z","timestamp":1788352286000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":15,"alternative-id":["10.1111\/bjh.70794"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70794","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"2026-06-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"bjh.70794"}}